PT-141 (Bremelanotide).
A brain-acting peptide that restores sexual desire and arousal — in both men and women.
Subcutaneous injection (as needed).Pricing is shown after your free assessment, before you commit.
Free to start. No card required.
Reviewed by Lumora clinical team (Licensed provider network)Mixed evidenceSource: Client-approved product catalog; provider review required
Evidence, regulatory status, and fit vary by medication, formulation, route, and individual history.
Is this for you?
This is for you if
- Adults with low libido or reduced sexual desire
- Patients who want a non-hormonal approach to sexual desire
- Patients who experience stress-related drops in desire
- Patients seeking improved arousal, responsiveness, and confidence
This isn't for you if
Possible side effects include nausea, flushing, headache, or transient blood pressure elevation. Not appropriate for patients with uncontrolled hypertension or cardiovascular disease. Disclose all medications before starting.
PT-141 (Bremelanotide)
PT-141, also called bremelanotide, is a peptide that activates melanocortin receptors in the brain involved in sexual desire and arousal. Unlike medications that work through blood flow (such as PDE5 inhibitors), PT-141 works at the level of the desire signal itself — and it is effective in both men and women.
Mechanism and fit.
PT-141 binds to melanocortin receptors in the central nervous system, particularly in regions that govern arousal and pleasure response. By restoring the desire signal at its source — rather than relying on circulation — PT-141 can help patients whose libido has been blunted by stress, hormonal changes, fatigue, or aging.
Who this is typically for.
- Adults with low libido or reduced sexual desire
- Patients who want a non-hormonal approach to sexual desire
- Patients who experience stress-related drops in desire
- Patients seeking improved arousal, responsiveness, and confidence
What patients
most often ask.
How is PT-141 different from Viagra or Cialis?
PDE5 inhibitors (Viagra, Cialis) work on blood flow. PT-141 works on desire — the upstream signal in the brain. They address different parts of sexual response and can be used together when appropriate.
Does PT-141 work for women?
Yes. Bremelanotide is FDA-approved for premenopausal women with hypoactive sexual desire disorder, and is used off-label for desire support in other populations under provider guidance.
When should I take it before intimacy?
Typically 30–45 minutes before. Effects usually last several hours.
Who this is typically for.
These are common fit patterns from the approved catalog. Your provider determines whether treatment is appropriate.
- <ul><li>Adults with low libido or reduced sexual desire</li><li>Patients who want a non-hormonal approach to sexual desire</li><li>Patients who experience stress-related drops in desire</li><li>Patients seeking improved arousal, responsiveness, and confidence</li></ul>
How this option
is evaluated.
The plan is provider-determined after reviewing your assessment and safety factors.
- DosingAs needed, typically 45 minutes before intimacy.
- Typical durationAs-needed use under provider guidance; long-term use is appropriate for many patients.
- Safety and eligibilityYour provider reviews contraindications, medication interactions, goals, and safety factors before prescribing.
- A licensed provider reviews your assessment before any treatment is recommended.
- You see full pricing - visit fees, medication, labs, follow-up - before you commit.
- Your plan can be adjusted, paused, or stopped based on response and safety. Your clinician is reachable - not a chatbot.
- Compounded medications are not FDA-approved and are dispensed only when prescribed by a licensed provider.
Start with
provider review.
If you are considering PT-141 (Bremelanotide), the first step is a free assessment. A provider determines whether it fits your goals and medical history.
A provider determines whether treatment is clinically appropriate.